Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4994322 | 1.00 | MAPK1 (0.36) | MAPK1ELANEPOLBCREBBPNOTUM | |
| SCHEMBL6824552 | 1.00 | MAPK1 (0.36) | MAPK1ELANEPOLBCREBBPNOTUM | |
| SCHEMBL23548373 | 0.82 | SMN1; SMN2 (0.33) | MAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL23548374 | 0.82 | SMN1; SMN2 (0.33) | MAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL4998227 | 0.80 | MEN1 (0.34) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4989211 | 0.80 | CHRNB2 (0.33) | PKMSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL6818549 | 0.78 | ALDH1A1 (0.40) | POLBPKMSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL23583803 | 0.76 | CHRM2 (0.37) | ELANEMEN1KMT2A | |
| SCHEMBL782700 | 0.76 | CHRM2 (0.37) | ELANEMEN1KMT2A | |
| SCHEMBL2134581 | 0.76 | CHRM2 (0.37) | ELANEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417153-B2 | Method for the production of 3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol derivatives | LONZA AG (CH) | 2008-08-26 | — | — | US | disclosed |
| US-20070043225-A1 | Method for the production of 3-amino-5-(hydroxymethyl) cyclopentane-1,2-diol-derivatives | LONZA AG (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070043225-A1 | Method for the production of 3-amino-5-(hydroxymethyl) cyclopentane-1,2-diol-derivatives | LONZA AG (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20040167351-A1 | Method for preparing (1R,4S)-2-azabicyclo[2.2.1]hept-5-ene-3-one derivatives | BERNEGGER-EGLI CHRISTINE (CH) | 2004-08-26 | — | — | US | disclosed |
| US-6780634-B1 | Method for producing (1R,4S)-2-azabicyclo[2.2.1]-hept-5-en-3-on derivatives | LONZA AG (CH) | 2004-08-24 | — | — | US | disclosed |
| EP-1095160-B1 | METHOD FOR PRODUCING (1R,4S)-2-AZABICYCLO 2.2.1 HEPT-5-EN-3-ON DERIVATIVES. | LONZA AG (CH) | 2004-01-28 | — | — | EP | disclosed |
| EP-1003903-B1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED N-DERIVATISED LACTAMS | GLAXO GROUP LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-6340587-B1 | TREATING RACEMIC MIXTURE WITH ACYLASE; ISOLATING PURE ENANTIOMORPH OF N-PROTECTED (1R,4S)-2-AZABICYCLO(2.2.1)HEPT-5-EN-3-ONE | SMITHKLINE BEECHAM CORPORATION | 2002-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043225-A1 | Method for the production of 3-amino-5-(hydroxymethyl) cyclopentane-1,2-diol-derivatives | SAT1, CYP8B1, ACMSD | MAPK1 1703/4885ELANE 2637/4885POLB 871/4885 |
| US-20040167351-A1 | Method for preparing (1R,4S)-2-azabicyclo[2.2.1]hept-5-ene-3-one derivatives | APEH, CYP51A1, CYP8B1 | MAPK1 3935/4885ELANE 886/4885POLB 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.